Renal Business Today

American Regent

American Regent Recalls Lot of Sodium Chloride Injection

WASHINGTON—American Regent initiated on June 14 a voluntary nationwide recall of one lot of its concentrated sodium chloride injection due visible particulates. ...More
June 16, 2011
Posted in News, Clinical & Pharma, Government & Regulation
Anemia Study Changed Way Docs Prescribe ESAs

EXTON, Pa.—Recent clinical reports on erythropoietin-stimulating agents have changed the way nephrologists are prescribing anemia drugs, according to recent survey results from BioTrends Research ...More
April 27, 2010
Posted in News, Business, Clinical & Pharma, Practice Management
Future Iron Treatments Shaped by New Payment Structures, Products

The choice of what iron product to use will be especially relevant with the bundled payment set to start in 2011. According to an August 2009 BioTrends report, dialysis clinic medical directors foresee the increased use of IV iron to spare the use of ESAs (such as Amgen’s ...More
January 29, 2010
Posted in Articles, Business, Clinical & Pharma, Practice Management
DaVita Gets DOJ Subpoena over Drug Claims

EL SEGUNDO, Calif.—Dialysis provider DaVita Inc. said Monday that it working to produce a wide range of documents related to pharmaceutical products in response to a federal subpoena that is connected to a civil investigation. ...More
December 15, 2008
Posted in News, Business, Clinical & Pharma, Government & Regulation
Top 10 Renal Stories of 2008

Years come and years go, but 2008 will long be remembered as the year that shaped the renal community for the 21st century. It was the year that the End-Stage Renal Disease Program saw some of its biggest changes in three decades, from the updated Conditions for Coverage as ...More
December 2, 2008
Posted in Articles, Business, Clinical & Pharma, Government & Regulation, Practice Management
U.S. regulators question Fresenius IV iron deal, set reimbursement terms

WASHINGTON—Before approving a deal in which dialysis provider Fresenius Medical Care obtained exclusive licensing rights to the drug Venofer, the U.S. Federal Trade Commission (FTC) raised competition concerns and set terms under which Fresenius wouldn’t be able to ...More
September 16, 2008
Posted in News, Business, Clinical & Pharma
Fresenius, Luitpold close licensing deal for IV iron drug

WASHINGTON—Dialysis provider Fresenius Medical Care and Luitpold have closed a deal under which Fresenius will obtain exclusive rights to manufacture, supply and distribute the IV iron drug Venofer to the U.S. end-stage renal disease population. ...More
September 16, 2008
Posted in News, Business, Clinical & Pharma
Anemia managers placing more emphasis on IV iron

EXTON, Pa.— Anemia managers for dialysis patients are more likely to report that they are using lower average doses of erythropoiesis-stimulating agents, monitoring hemoglobins more frequently and placing more emphasis on a patient's IV iron status, according to a report ...More
September 12, 2008
Posted in News, Business, Clinical & Pharma
Fresenius signs deal to market IV iron drugs

BAD HOMBURG, Germany—Fresenius Medical Care said today that it has signed an exclusive licensing agreement for the intravenous iron products Venofer and Injectafer to treat iron deficiency anemia in dialysis patients. ...More
July 9, 2008
Posted in News, Business, Clinical & Pharma
What's Next in Dialysis Iron Management?

Iron is on the minds of many Americans, especially with the superhero movie “Iron Man” raking in $100 million its first weekend in theatres. But hundreds of thousands of people have other reasons to think about iron, as it is a vital nutrient dialysis patients ...More
May 21, 2008
Posted in Articles, Business, Clinical & Pharma

featured links

HOT TOPICS

Computers & Software	Consulting, Management...
Equipment & Services	Hemodialysis Supplies
Patient Services	More Options...

American Regent

Mobile Health Snaps

Galleries

Most Popular Articles

Buyer's Guide

Resources

Free Email Updates

featured links

First Name	Last Name
E-Mail